Fred Driscoll

Frederick W.
Driscoll currently works at Lite Strategy, Inc., as Non-Executive Chairman from 2024, Cellectar Biosciences, Inc., as Independent Director from 2017, SmartPharm Therapeutics, Inc., as Director from 2019, NeoSoma, Inc., as Director from 2023, and Adipo Therapeutics LLC, as Director.
Mr. Driscoll also formerly worked at Oncotelic Therapeutics, Inc., as Chairman, President & Chief Executive Officer from 2000 to 2006, Genelabs Technologies, Inc., as President & Chief Executive Officer from 2008 to 2009, NantKwest, Inc., as Lead Independent Director, Cynapsus Therapeutics, Inc., as Director in 2016, Abpro Corp., as Independent Director, Cue Biopharma, Inc., as Independent Director from 2018 to 2025, ImmunityBio, Inc., as Director, Calliditas Therapeutics AB, as Independent Non-Executive Director, Novavax, Inc., as Chief Financial Officer, Treasurer & VP from 2012 to 2013, ConforMIS, Inc., as Chief Financial Officer & Treasurer from 2019 to 2020, Flexion Therapeutics, Inc., as Chief Financial Officer from 2013 to 2017, Flexion Therapeutics, Inc., as Chief Financial Officer in 2021, Instrumentation Laboratory Co., as Vice President-Finance-Americas & Controller from 1974 to 2006, Astraris, Inc., as Chief Financial Officer from 2006 to 2007, Collagenesis Corp., as Senior Vice President-Finance & Operations from 1996 to 2000, Renovacor, Inc., as Secretary, Chief Financial & Accounting Officer, and Invivyd, Inc., as Chief Financial Officer from 2022 to 2023.
Mr. Driscoll received his undergraduate degree in 1972 from Bentley University.